Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Zevra Therapeutics, Inc. (ZVRA) stock profile

Zevra Therapeutics, Inc. is a rare disease company that discovers and develops proprietary prodrugs to treat serious medical conditions in the United States. The company leverages its Ligand Activated Therapy technology to create improved versions of FDA-approved drugs and prodrug candidates for new disease indications. Its pipeline focuses on attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. The lead product candidate KP1077, in Phase II clinical trials for idiopathic hypersomnia and narcolepsy, is based on serdexmethylphenidate, a prodrug of d-methylphenidate. The company is also developing KP879 for stimulant use disorder, which is in Phase II trials. Zevra has received FDA approval for AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, with acetaminophen. The company has collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Originally incorporated as KemPharm, Inc. in 2006, the company changed its name to Zevra Therapeutics, Inc. in February 2023 and is headquartered in Celebration, Florida.

Key facts

SymbolZVRA
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEONeil F. McFarlane
Employees59
HeadquartersCelebration, FL, US
IPO2015-04-16
Websitezevra.com

Explore ZVRA on Vantafin

  • Zevra Therapeutics, Inc. Overview
  • Zevra Therapeutics, Inc. Financials
  • Zevra Therapeutics, Inc. News
  • Zevra Therapeutics, Inc. Events
  • Zevra Therapeutics, Inc. SEC filings
  • Zevra Therapeutics, Inc. Insider transactions
  • Zevra Therapeutics, Inc. Transcripts

Frequently asked questions

What does Zevra Therapeutics, Inc. (ZVRA) do?
Zevra Therapeutics, Inc. is a rare disease company that discovers and develops proprietary prodrugs to treat serious medical conditions in the United States. The company leverages its Ligand Activated Therapy technology to create improved versions of FDA-approved drugs and prodrug candidates for new disease indications. Its pipeline focuses on attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. The lead product candidate KP1077, in Phase II clinical trials for idiopathic hypersomnia and narcolepsy, is based on serdexmethylphenidate, a prodrug of d-methylphenidate. The company is also developing KP879 for stimulant use disorder, which is in Phase II trials. Zevra has received FDA approval for AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, with acetaminophen. The company has collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Originally incorporated as KemPharm, Inc. in 2006, the company changed its name to Zevra Therapeutics, Inc. in February 2023 and is headquartered in Celebration, Florida.
Where is ZVRA stock listed?
Zevra Therapeutics, Inc. trades under the ticker ZVRA on NASDAQ.
How can I research ZVRA's financials and filings?
Vantafin provides Zevra Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ZVRA profile.